PTX.AX Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 bal. 2024 @ 09:10):

Stats
Šios dienos apimtis	762 848
Vidutinė apimtis	1.17M
Rinkos kapitalizacija	41.88M
EPS	$0 ( 2024-02-21 )
Last Dividend	$7.15 ( 1993-10-21 )
Next Dividend	$0 ( N/A )
P/E	-5.20
ATR14	$0.00100 (1.89%)

Prescient Therapeutics Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Prescient Therapeutics Finansinės ataskaitos

Annual	2023
Pajamos:	$2.43M
Bruto pelnas:	$2.43M (99.91 %)
EPS:	$-0.00960

FY	2023
Pajamos:	$2.43M
Bruto pelnas:	$2.43M (99.91 %)
EPS:	$-0.00960

FY	2022
Pajamos:	$1.89M
Bruto pelnas:	$1.89M (99.93 %)
EPS:	$-0.00790

FY	2021
Pajamos:	$0.00
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-0.00680

Financial Reports:

No articles found.

Prescient Therapeutics Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Prescient Therapeutics Dividend Information - No Dividend Player

Dividend Sustainability Score: 0 - low (50.00%) | Divividend Growth Potential Score: 0 - No dividend growth expected in the near future

Information

First Dividend	$5.72	1990-10-25
Last Dividend	$7.15	1993-10-21
Next Dividend	$0	N/A
Payout Date	1993-12-31
Next Payout Date	N/A
# dividends	2	--
Total Paid Out	$12.87	--
Avg. Dividend % Per Year	0.00%	--
Score	0.22	--
Div. Sustainability Score	0
Div.Growth Potential Score	0
Div. Directional Score	0	--

Next Divdend (Est)
(2026-10-05)

$0 Estimate 0.00 %

Dividend Stability

0.00 Very Bad

Dividend Score

0.22

Pay Frequency

Sporadic

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company does not currently pay dividends. Given its current dividend status and a low Dividend Growth Potential Score (DGPS), there's minimal likelihood of dividends being initiated soon. Considering all factors, the near-term dividend outlook for the company remains unpromising.

Top 10 dividend Companies for ASX

Symbol	Title	Last dividend	Frequency	Yearly Dividend
MXT.AX	Ex Dividend Knight	2023-08-31	Monthly	0.00%
WBC.AX	Ex Dividend Junior	2023-05-11	Annually	0.00%
EHL.AX	Ex Dividend Knight	2023-09-07	Sporadic	0.00%
PCG.AX	Ex Dividend Junior	2023-08-29	Annually	0.00%
ALU.AX	Ex Dividend Knight	2023-09-04	Semi-Annually	0.00%
GUD.AX	Ex Dividend Knight	2023-08-25	Semi-Annually	0.00%
RFF.AX	Ex Dividend Knight	2023-09-28	Quarterly	0.00%
BRG.AX	Ex Dividend Knight	2023-09-13	Semi-Annually	0.00%
KSL.AX	Ex Dividend Knight	2023-09-06	Semi-Annually	0.00%
SRV.AX	Ex Dividend Knight	2023-09-04	Semi-Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-2.49	1.500	-10.00	-10.00	[0 - 0.5]
returnOnAssetsTTM	-0.313	1.200	-10.00	-10.00	[0 - 0.3]
returnOnEquityTTM	-0.318	1.500	-4.65	-6.97	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	10.26	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	9.96	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	3.08	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	0	1.000	-1.111	-1.111	[3 - 30]
operatingCashFlowPerShareTTM	-0.00952	2.00	-0.00317	-0.00635	[0 - 30]
freeCashFlowPerShareTTM	-0.00952	2.00	-0.00476	-0.00952	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	1.000	1.000	10.00	10.00	[0.2 - 0.8]
operatingProfitMarginTTM	-3.71	1.000	-10.00	-10.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0.126	0.800	-2.50	-1.996	[0.5 - 2]
Total Score				-0.920

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-5.51	1.000	-0.658	0	[1 - 100]
returnOnEquityTTM	-0.318	2.50	-2.99	-6.97	[0.1 - 1.5]
freeCashFlowPerShareTTM	-0.00952	2.00	-0.00317	-0.00952	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-0.00952	2.00	-0.00317	-0.00635	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	-1.911	1.500	-10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-2.46	1.000	-10.00	0	[0.1 - 0.5]
Total Score				-2.81

Prescient Therapeutics

Prescient Therapeutics Limited, a clinical stage oncology company, develops novel drugs for the treatment of various cancers in Australia. Its lead drug candidate is PTX-200, which is in Phase 2a clinical trial for HER2-negative breast cancer, Phase IB/2 clinical trial in relapsed and refractory AML, and Phase 1b in recurrent or persistent platinum-resistant ovarian cancer; and PTX-100, a RhoA inhibitor, for hematological and solid malignancies that focuses on cancers with Ras and RhoA mutations. It has a strategic collaboration with The University of Texas MD Anderson Cancer Center to develop blood cancer binder for OmniCAR. The company was formerly known as Virax Holdings Limited and changed its name to Prescient Therapeutics Limited in December 2014. Prescient Therapeutics Limited was incorporated in 1986 and is based in Melbourne, Australia.